Decode News AI
简体繁體

Eli Lilly Signs Cancer Research Deal With Stipple Bio Worth Up to $5.9 Billion

2026-11-17 02:47 EST · AI-compiled · 239 words · about 1 min · Views …

CAMBRIDGE, Mass. - Eli Lilly signed a multi-target oncology research and licensing deal with privately held Stipple Bio on Nov. 16 worth up to $5.9 billion in milestones. Lilly will also pay an undisclosed upfront fee and equity investment for exclusive global rights to develop and commercialize resulting therapies.

Platform Targets Tumor Surface Markers to Limit Toxicity

Stipple Bio will use its Pointillist Platform to find binders for tumor-specific cell surface epitopes for Lilly's oncology programs. "Stipple Bio was founded with the belief that epitope-level precision could distinguish tumor cells from healthy tissue, unlocking a new generation of effective and safer cancer therapies directed at targets whose expression on healthy cells has historically limited their clinical utility," CEO Jeff Landau said on GlobeNewswire.

Deal Expands Lilly Oncology Pipeline Beyond Weight-Loss Drugs

Stipple Bio is eligible for up to $5.9 billion in research, development, and commercial milestone payments plus tiered royalties on future sales. The alliance bolsters Lilly's cancer lineup beyond breast cancer drug Verzenio and blood cancer treatment Jaypirca as it diversifies outside blockbuster diabetes and obesity medicines.

Biotech Partner Advances Internal Solid-Tumor Candidate for 2027

Alongside the Lilly collaboration, Cambridge-based Stipple Bio plans to launch a Phase 1 clinical trial of its antibody-drug conjugate STP-100 in early 2027 for solid tumors including pancreatic cancer. Stipple Bio was named to the 2026 Endpoints 11 list, while Lilly declined further comment.

Sources

Found a factual error or typo? Tell us

Follow Decode News AI on Telegram

Live updates: every new story is pushed the moment it publishes — dozens a day, no digest delay.

@decodenewsai · Subscribe now

Free · unsubscribe anytime

Comments